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Joubert syndrome and related disorders are autosomal
recessive multisystem diseases characterized by cerebellar
vermis aplasia/hypoplasia, retinal degeneration and cystic
kidney disease. There are five known genes; mutations of
which give rise to a spectrum of renal cystic diseases the
most common of which is nephronophthisis, a disorder
characterized by early loss of urinary concentrating ability,
renal fibrosis, corticomedullary cyst formation and renal
failure. Many of the proteins encoded by these genes interact
with one another and are located at adherens junctions or
the primary cilia and or basal bodies. Here we characterize
Jouberin, a multi-domain protein encoded by the AHI1 gene.
Immunohistochemistry with a novel antibody showed that
endogenous Jouberin is expressed in brain, kidney and
HEK293 cells. In the kidney, Jouberin co-localized with
aquaporin-2 in the collecting ducts. We show that Jouberin
interacts with nephrocystin-1 as determined by yeast-2-
hybrid system and this was confirmed by exogenous and
endogenous co-immunoprecipitation in HEK293 cells.
Jouberin is expressed at cell-cell junctions, primary cilia and
basal body of mIMCD3 cells while a Jouberin-GFP construct
localized to centrosomes in subconfluent and dividing MDCK
cells. Our results suggest that Jouberin is a protein whose
expression pattern supports both the adherens junction and
the ciliary hypotheses for abnormalities leading to
nephronophthisis.
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Joubert syndrome and related disorders (JBTS)1 are a group
of inherited recessive neurological diseases characterized by
cerebellar vermis aplasia/hypoplasia and retinal degenera-
tion.2,3 The syndrome is characterized neuroradiologically by
the ‘molar tooth sign’ secondary to cerebellar vermis aplasia,
prominent superior cerebellar peduncles, and a deep
interpeduncular fossa.4 Patients exhibit developmental delay,
mental retardation, loss of muscle tone, irregular breathing
patterns, and abnormal eye movements.1 In addition to these
core features patients may exhibit cystic kidney disease and
nephronophthisis (NPHP), these patients being termed JBTS
type B or cerebello-oculo-renal syndrome.5 The monogenic
causes of JBTS have recently been discovered. There are now
five known genes implicated (NPHP1, AHI1, NPHP6/
CEP290, RPGRIP1L/NPHP8, and MKS3/TMEM67) and a
further two loci (JBTS1/CORS1 on chromosome 9q34.3 and
JBTS2/CORS2 on chromosome 11p12-11q33.3)5–7 have been
well described. Mutations in all of these genes, or at these
loci, may all give rise to renal cystic disease, most commonly
NPHP. NPHP is characterized by an early loss of urinary
concentration ability, progressive interstitial fibrosis, tubular
basement membrane disruption, and corticomedullary cyst
formation. It is the most common cause of renal failure in
children and young adults.8
AHI1 (Abelson helper integration-1), a gene that encodes
for the protein Jouberin, is mutated in 10–15% of cases of the
autosomal recessive disease JBTS.9 Expression studies to date
are limited to brain expression of Jouberin mRNA10,11 and
expression studies in haematopoietic cells.12 The domain
structure of the Jouberin protein, which includes an Src
homology 3 (SH3) domain and six or seven WD40 domains
(in human and mouse, respectively) is in keeping with other
adapter proteins.
NPHP1 mutations are the most common genetic cause of
NPHP, accounting for 25% of all cases of NPHP.13,14
Mutations are commonly a homozygous gene deletion (in
85% of cases) or a heterozygous deletion with a single point
mutation on the second allele.15 Recently, mutations in
NPHP1 have been found in a subset of patients with JBTS16
and probably account for 1–2% of the total of all JBTS
patients.9 On the basis of mutation analysis of AHI1 and
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NPHP1, an epistatic interaction between Jouberin and
nephrocystin-1 has recently been postulated.17 Domain
analysis of the nephrocystin-1 protein reveals a coiled-coil
domain together with a SH3 domain. Nephrocystin-1 is
known to interact with p130Cas (alias BCAR1) through its
SH3 domain, binding to the PXXP motif.18 Because
nephrocystin proteins and Jouberin possess multiple inter-
action domains and coiled-coil domains this allows specula-
tion that these proteins form multiple protein–protein
interactions and function as a large complex. In addition,
the pattern of subcellular localization of nephrocystin
proteins, with a predominantly cilial/basal body localization
also points toward a functional complex of nephrocystin
proteins and implicates the primary cilia in disease
pathogenesis.19
Given the variable renal phenotype and the genetic overlap
with other NPHP-causing genes, we investigated the expres-
sion pattern and protein interactions of Jouberin in renal
cells, in order to try and understand possible mechanisms of
renal disease in JBTS. Intriguingly, many of the nephrocystin
proteins, together with polycystins, BBS proteins and MKS
proteins, collectively known as ‘cystoproteins’ because of
their renal cystic phenotype if mutated, have been shown to
localize to distinct cell compartments. These include primary
cilia, centrosomes, and basal bodies thus suggesting a role for
these structures in cystic kidney disease.20,21 This ciliary
localization of nephrocystin proteins may be combined with
a cell–cell junction localization.13,22 Data concerning whole
kidney expression of nephrocystins are extremely sparse due
to a lack of specific antibodies. In particular, the expression
pattern of Jouberin within the kidney and its molecular
interactions remain unknown. Here we demonstrate that
Jouberin is expressed in human and mouse brain and kidney,
in addition to the ciliated renal epithelial cell lines human
embryonic kidney (HEK293), murine inner medullary
collecting duct (mIMCD3), and Madin–Darby canine kidney
(MDCK) cells. We demonstrate that Jouberin interacts with
nephrocystin-1 and that Jouberin colocalizes at cell–cell
contacts with b-catenin. Expression of a Jouberin–green
fluorescent protein (GFP) construct demonstrates a centro-
somal localization and in confluent mIMCD3 cells we
demonstrate that Jouberin associates with acetylated a-
tubulin in the primary cilium. Finally, in human kidney,
Jouberin expression is seen in renal collecting duct cells,
colocalizing with aquaporin-2 (AQP2).
RESULTS
Jouberin is a multidomain protein
Sequence analysis of the Jouberin peptide sequence reveals a
high degree of conservation between human and mouse
Jouberin, with amino-acid identity 80%. The main difference
between these two species is the presence of 140 N-terminal
amino acids in the human Jouberin, which are absent
from the murine Jouberin. Domain analysis (http://smart.
embl-heidelberg.de/ and http://www.ch.embnet.org/software/
COILS) reveals that both human and murine N-terminal
sequences encode a coiled-coil domain. Both human and
murine Jouberin and nephrocystin-1 proteins possess a SH3
domain which may bind to target proteins through sequences
containing proline and hydrophobic amino acids.23 Finally,
the human Jouberin protein contains six WD40 domains,
whereas the murine Jouberin has seven WD40 domains
(Figure 1a).
Yeast 2-hybrid interactions between Jouberin and
nephrocystin-1
Direct yeast 2-hybrid experiments were performed between
the full-length human nephrocystin-1 and full-length Jou-
berin and a series of Jouberin subclones (Figure 1b). The SH3
domain subcloned from nephrocystin-1 was also used for
these studies. Results (shown in Figure 1c) demonstrate that
nephrocystin-1 interacts with Jouberin. This interaction
persists while using subclones of Jouberin, which contain
WD40 domains and the SH3 domain from nephrocystin-1.
When bait and prey are reversed, the Jouberin clone
containing WD40 domains 5 and 6 (subclone Jouberin_C)
is the only positive interaction (Figure 1c). Positive controls
for these interaction studies include confirming an yeast
interaction between nephrocystin-1 and the SH3-binding
domain of nephrocystin-4 and between nephrocystin-1 and
p130Cas, which has a PXXP motif, known to bind to the SH3
domain.24 Appropriate negative controls were used to
exclude self-activation of the yeast constructs (Figure 1c).
Jouberin is endogenously expressed in brain and kidney
Reverse transcriptase-PCR analysis of Jouberin mRNA
confirms its expression in human brain and kidney (Figure 2a),
mouse brain and kidney (Figure 2b), and in renal epithelial
cell lines HEK293, mIMCD3, and MDCK cells (Figure 2c).
Using a novel anti-Jouberin antibody (Ab737) directed
toward a peptide at the C-terminus of Jouberin (Figure 1a),
Western blotting revealed bands of approximately 160 kDa in
size in HEK293, mIMCD3, and MDCK cells, respectively, as
well as adult mouse kidney and brain (Figure 3a). There are
some 4250 kDa bands seen in HEK293 and MDCK cells,
which are peculiar to these cell lines and are likely to be
nonspecific. An additional smaller Jouberin isoform
(B120 kDa) is seen in mIMCD3 cells and mouse kidney.
Database searches do not predict a Jouberin isoform of this
length, suggesting this may be a novel kidney-specific isoform
of Jouberin. Peptide preabsorption was able to block
detection by the antibody of the expected (B165 kDa) and
smaller (B120 kDa) isoforms; demonstrating specificity of
the antibody, and Western blotting using preimmune sera
was negative (Figure 3a). The specificity of the anti-Jouberin
Ab737 antibody was also confirmed using overexpression of
Jouberin–GFP in HEK293 cells. The anti-Jouberin Ab737
detected the endogenous band in addition to a higher
molecular weight band corresponding to the GFP fusion
protein. Anti-GFP antibodies detected the same weight band
only in transfected cells (Figure 3b). Using an alternative
anti-Jouberin (Ab7367) antibody directed toward a peptide
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Figure 1 | Domain structure of Jouberin and yeast 2-hybrid interaction studies. (a) Schematic representation of the human and mouse
isoforms of Jouberin and human nephrocystin-1 protein with their predicted protein domains (using http://smart.embl-heidelberg.de/ and http://
www.ch.embnet.org/software/COILS). Each protein sequence is depicted by a straight line with known protein domains represented by colored
boxes at their relative positions in the sequence, with amino-acid numbers given for the start and end of each domain. For Jouberin, the antigenic
sequences used to generate antibodies Ab736 and Ab737 are also shown as black bars. CC, coiled coil; WD40, WD40 repeats; SH3,
Src homology-3. (b) Schematic representation of subclones of Jouberin (Jouberin_A, Jouberin_B, and Jouberin_C) and the SH3 domain from
nephrocystin-1 protein. The amino-acid residues of each clone are shown, in comparison to the full-length clones shown in (a). Known protein
domains within the subclones are shown as in (a). (c) In yeast 2-hybrid direct interaction analysis, human nephrocystin-1 as bait interacts with
human Jouberin as prey. This interaction is partially mapped with nephrocystin-1 failing to interact with Jouberin_A, but interacting with
Jouberin_B and Jouberin_C. In reciprocal interactions Jouberin_C (bait) is able to interact with SH3 domain of nephrocystin-1 (Nephrocystin-1_SH3),
implicating the WD40 domains of Jouberin and the SH3 domain of nephrocystin-1 in this interaction. Empty-vector controls are shown. Positive
controls show that nephrocystin-1 interacts with nephrocystin-4 and p130Cas. Interaction strength controls 1–4 are also shown. Strength of the
interaction is scored by colony growth on triple drop out medium, as compared to controls. Control for colony growth is shown on medium
deficient in leucine (–Leu) and tryptophan (–Trp). Red color in certain control colonies is expected to occur upon starvation for specific amino acids.
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corresponding to amino-acid positions 379–393 in human
Jouberin (Figure 1a), Western blotting also reveals bands of
approximately 160 kDa in MDCK, HEK293, and mIMCD3
cells. Preimmune sera do not detect these bands (Figure 3c).
Coimmunoprecipitation of Jouberin and nephrocystin-1
In order to confirm yeast interactions we used exogenous
expression of Jouberin and nephrocystin-1 cDNA constructs
in HEK293 cells. The interaction between nephrocystin-1 and
human Jouberin was confirmed using coimmunoprecipita-
tion of V5 and Flag-tagged constructs. Flag-tagged nephro-
cystin-1 was co-precipitated with V5-tagged Jouberin using
anti-Flag antibodies, and confirmed using reciprocal coim-
munoprecipitation using anti-V5 antibody (Figure 4a and b).
This interaction was also demonstrated using a murine
Jouberin construct, which is identified at a lower molecular
weight than the human Jouberin construct (Figure 4c). This
difference in mass corresponds to a predicted difference in
molecular weight of 22 kDa between the human and mouse
proteins encoded by the exogenously expressed cDNA
constructs. As a positive control for our system of exogenous
overexpression we confirmed by coimmunoprecipitation the
known interaction between nephrocystin-1 and p130Cas
(data not shown). We further confirmed the interaction
between Jouberin and nephrocystin-1 using endogenous
expression in HEK293 cells and coimmunoprecipitation.
Using anti-Jouberin conjugated to protein A, nephrocystin-1
coimmunoprecipitates with Jouberin (Figure 4d). Using site-
directed mutagenesis, we prepared a Jouberin construct
containing a missense mutation, R830W. This AHI1 muta-
tion has previously been identified in JBTS patients with
NPHP1 or NPHP6 mutations,17 but its functional signifi-
cance at the protein level is unknown. Using coimmunopre-
cipitation experiments in HEK293 cells, we confirm that this
mutation alone is not sufficient to abrogate the interaction.
Coexpression of Jouberin-R830W and nephrocystin-1 pro-
teins are still able coimmunoprecipitate together (Figure 4e).
Endogenous Jouberin is expressed at cell–cell contacts in
renal epithelium and is a part of the cilial/centrosomal
complex
Endogenous expression of Jouberin was observed in the
cytoplasm and cell–cell contacts in polarized mIMCD3 cells
using anti-Jouberin Ab737 antibody (Figure 5a). The staining
toward Jouberin is highly specific, fully blocked by pre-
incubation of the primary antibody with its peptide, and
preimmune serum gave no signal (Figure 5a). Double
staining with Jouberin antibody and an antibody directed
toward b-catenin, an adherens junction-associated protein,
demonstrates partial colocalization in mIMCD3 cells (Figure
5b). Anti-Jouberin Ab736 did not work well for immuno-
fluorescence studies.
Using a GFP-tagged Jouberin construct transfected MDCK
cells of low confluence revealed diffuse cytoplasmic staining,
together with specific staining resembling basal bodies,
colocalizing with g-tubulin, a basal body marker, in a cell
during interphase (Figure 5c). In a cell undergoing mitosis,
Jouberin–GFP can be seen at the spindle poles (Figure 5d). In
confluent, post-mitotic mIMCD3 cells, left 96 h past the
point of confluency to allow optimal ciliogenesis, anti-
Jouberin antibodies demonstrate punctuate staining that is
associated with acetylated a-tubulin (Figure 6).
Endogenous Jouberin is expressed in human renal collecting
duct cells
Immunofluorescent staining using Jouberin Ab737 on hu-
man kidney sections containing renal cortex and medulla
identified a subset of nephron segments expressing Jouberin
(Figure 7a). Omitting Jouberin antibody and using pre-
immune sera demonstrates specificity of the antibody (Figure
7a). Jouberin staining nephron segments resembled collecting
ducts. Therefore, using double staining with Jouberin and
AQP2 antibodies, we demonstrate Jouberin expression in
collecting duct segments with AQP2 staining at the apical
plasma membranes and subapical regions (Figure 7b and c).
Jouberin staining in collecting duct cells appears near plasma
membranes, both basolaterally and apically. The staining
pattern of Jouberin is restricted to collecting ducts, with
neighboring (AQP2 negative) tubules demonstrating an
absence of Jouberin expression. Control sections, which
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Figure 2 | RT-PCR expression of Jouberin. RT-PCR products are
visualized on a 0.8% agarose gel using Jouberin-specific (and
species specific) oligonucleotide primers. (a) RT-PCR products of
the expected size (474 bp) are seen using human brain and kidney
total RNA as template. (b) RT-PCR products of the expected size
(578 bp) are seen using mouse brain and kidney total RNA as
template. For (a, b), negative controls 1 and 2 omitted RT enzyme
for brain and kidney samples, respectively, controls 3 and 4
omitted RNA. (c) RT-PCR products of the expected sizes (474, 578,
and 329 bp, respectively) are seen using total RNA extracted from
HEK293, mIMCD3, and MDCK cells as templates. Negative controls
1, 2, and 3 omitted RT enzyme for each template, respectively,
controls 4 and 5 omitted RNA. L, DNA size ladder (100 bp ladder;
New England Biolabs, Ipswith, MA).
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omitted primary Jouberin or AQP2 antibodies, revealed no
staining, excluded cross-reaction of secondary antibodies.
DISCUSSION
Using a novel antibody, we have established the presence of
endogenous renal expression of Jouberin protein. This is in
keeping with the kidney phenotype of JBTS with renal
involvement (JBTS type B/cerebello-oculo-renal syndrome),
which includes urinary concentration defects, NPHP and
cystic kidneys.
Mutations in AHI1, the gene encoding for Jouberin,
account for around 10–15% of patients with JBTS,3 with renal
involvement occurring as a variable phenotype.25–27 Other
JBTS causing gene defects also display a variable phenotype,
with NPHP1 mutations giving a prominent renal phenotype
and NPHP6 mutations giving a prominent retinal pheno-
type.26,28 This variable phenotype may be due to different
tissue expression of the protein but also may be secondary to
oligogenicity, as discussed below.
Using yeast interaction studies we demonstrate that
nephrocystin-1 interacts with Jouberin. Furthermore, this
interaction was present using both full-length clones and
using subclones of Jouberin, which contained WD40
domains 1–5 and WD40 domains 5–6, thus partially mapping
the interaction. Coimmunoprecipitation experiments
confirmed this interaction between nephrocystin-1 and
Jouberin, both in exogenous expression systems and using
endogenous coimmunoprecipitation (Figure 4). Given that
mutations in either NPHP1 or AHI1 may be seen in JBTS
patients, our results strengthen the hypothesis that there is a
functional interaction between nephrocystin-1 and Jouberin.
This is relevant to mechanisms of human disease, as a
possible genetic (epistatic) interaction has been described
between NPHP1 and AHI1 in JBTS patients. Tory et al.
describe five patients with NPHP1 mutations whom also
carried a R830W mutation in AHI1,17 which interestingly lies
just before the fifth WD40 domain of Jouberin. These
patients had more prominent neurological manifestations of
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Figure 3 | Endogenous Jouberin expression and characterization of novel anti-Jouberin antibody. (a) Western blotting using the
Jouberin (Ab737) antibody reveals bands of approximately 165 kDa in cell lines HEK293, mIMCD3, and MDCK, and mouse brain and kidney
tissue. A smaller isoform (B120 kDa) is noted in mIMCD3 and mouse kidney. Incubation of antibody with peptide blocks detection of the
B165 kDa bands and the smaller isoforms. In addition, no bands are seen in the preimmune control. (b) Using HEK293 cells Jouberin–GFP
was overexpressed. Cell lysates probed with anti-Jouberin antibodies revealed endogenous expression and an additional higher molecular
weight band corresponding to Jouberin–GFP fusion protein (absent in control untransfected cells; upper panel). Anti-GFP antibody
confirmed the expression of Jouberin–GFP in transfected cells (lower panel). (c) Western blotting using the Jouberin (Ab736) antibody
reveals bands of approximately 165 kDa in cell lines MDCK, HEK293, and mIMCD3. These bands are not seen in the preimmune control.
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the disease.17 WD40 domains seem to be functionally
important for the interaction between Jouberin and nephro-
cystin-1. The Jouberin R830W missense mutation is not
sufficient to prevent the interaction between Jouberin
and nephrocystin-1 when these proteins are exogenously
expressed.
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Figure 4 | Coimmunoprecipitation of Jouberin with nephrocystin-1. (a, b) Human nephrocystin-1 interacts with human Jouberin.
HEK293 cells were co-transfected with constructs containing human nephrocystin-1 tagged with Flag and human Jouberin tagged with V5.
(a) Using anti-Flag on protein G, detection with anti-Flag showed that human nephrocystin-1 was able to immunoprecipitate nephrocystin-
1 (left panel) and detection with anti-V5 antibody showed that human nephrocystin-1 could coimmunoprecipitate human Jouberin (right
panel). (b) Using anti-V5 on protein G, detection with anti-V5 showed that human Jouberin was able to immunoprecipitate Jouberin (left
panel) and detection with anti-Flag antibody showed that human Jouberin could coimmunoprecipitate human nephrocystin-1 (right panel).
(c) Human nephrocystin-1 interacts with mouse Jouberin. HEK293 cells were co-transfected with constructs containing human
nephrocystin-1 tagged with Flag and mouse Jouberin tagged with V5. Using anti V5 on protein G, detection with anti-V5 showed that
mouse Jouberin was able to immunoprecipitate Jouberin (left panel) and detection with anti-Flag antibody showed that mouse Jouberin
could coimmunoprecipitate human nephrocystin-1 (right panel). (d) Human nephrocystin-1 interacts with Jouberin in HEK293 cells. Lysates
from untransfected HEK293 were immunoprecipitated using anti-nephrocystin-1 on protein A (lane 2), and using anti-Jouberin on protein A
(lane 3). (e) Nephrocystin-1 interacts with Jouberin-R860W-mutant protein. HEK293 cells were co-transfected with constructs containing
human Nephrocystin-1 tagged with Flag and Jouberin-R830W tagged with V5. Using anti-V5 on protein G, detection with anti-V5 showed
that mutated Jouberin-R830W was able to immunoprecipitate itself (left panel) and detection with anti-Flag antibody showed that mutated
Jouberin-R830W was able to coimmunoprecipitate nephrocystin-1 (right panel). In all experiments negative controls including
untransfected cells, no antibody on protein G or A and mouse/rabbit IgG substituting the detecting antibody.
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Given we have shown Jouberin expression at cell–cell
contacts, with colocalization with b-catenin, this suggests
that Jouberin, like nephrocystin-129 and nephrocystin-4,22 is
an adherens junction-associated protein. This adherens
junction role for nephrocystin proteins is supported by
known interaction between nephrocystin-1 and p130Cas
(alias BCAR1) and PTK2B.30 Colocalization of Jouberin
with b-catenin may also implicate Jouberin in functional
pathways including Wnt signalling,31 which may play key
roles in determining proliferation rates, polarity, and
organogenesis.
Like other nephrocystins, Jouberin expression was not
limited to one subcellular compartment, as we also show a
centrosomal and ciliary localization. Jouberin–GFP coloca-
lizes with centrosomal structures and its localization during
cell division appears dynamic, in a similar manner to
inversin32,33 and nephrocystin-6.28 In confluent cells we are
able to show association in a punctuate manner with
acetylated a-tubulin in the axoneme of the primary cilia.
This observation implicates the pathogenesis of JBTS is
caused by a defect in primary ciliary structure or function, in
a similar manner to other ‘cystoproteins’.19 Thus, like
OverlayJouberin-GFP Acetylated α-tubulin
OverlayJouberin-GFP γ-tubulin
OverlayJouberin-Ab737 β-catenin
Peptide blockJouberin-Ab737 Pre-immune
Figure 5 | Jouberin is expressed both at the adherens junction and centrosomal complex in renal epithelial cells. mIMCD3 cells were
grown in a confluent monolayer (for 5 days) before fixation. Midcell confocal sections were examined after methanol fixation and stained
with (a) anti-Jouberin (green) with preimmune serum staining and peptide-blocking controls shown below. (b) Co-staining with
anti-Jouberin (green) and anti-b-catenin antibody (red). MDCK cells transfected with Jouberin–GFP cDNA were fixed in paraformaldehyde.
(c) Transfected cell (in interphase) counterstained with g-tubulin (red), to highlight centrosomes. (d) A transfected cell (undergoing mitosis)
is counterstained with acetylated a-tubulin antibodies (red). Bar¼ 10mm.
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nephrocystin-4,22 Jouberin is a protein whose expression
pattern supports both an adherens junction hypothesis and a
ciliary hypothesis for mechanism leading to NPHP.19
Finally, in human kidney, we are able to show that
Jouberin is expressed in renal tubules. This may not be
surprising to note, given the renal phenotype, but the study
of Jouberin expression in human renal tissue is completely
novel. Furthermore, expression of Jouberin was limited to
tubules expressing AQP2, namely the renal collecting duct
cells. This is highly topical as inherited renal cystic diseases,
such as neophronophthisis, are associated with a loss of
ability to concentrate urine.34–38 Typically, a patient with
NPHP will develop symptoms of polydipsia and polyuria at
the age of 4–6 years, related to the underlying defect in urine
concentration ability and a failure to concentrate urine
following a water deprivation test is a characteristic finding in
NPHP.8 In compensation for this inability to concentrate
urine, the vasopressin V2 receptor and APQ2 protein are
overexpressed in vivo in mouse models of cystic kidney
disease.39–41 This concentrating defect has previously been
attributed to the progressive renal impairment or the
disruption of renal medullary anatomy by cysts. However,
such concentrating defects seem to precede collecting duct
cyst formation in animal models of cystic kidney disease. In
patients with NPHP, cyst formation and end-stage renal
failure is typically reached at 12–13 years of age, many years
after symptomatic urinary concentrating defects have been
noted. These clinical observations, combined with various
mouse models of cystic kidney disease, including NPHP (the
pcy mouse20) have lead to the use of vasopressin receptor
antagonists as a therapeutic agent to treat cystogenesis.42
Given the collecting duct distribution of Jouberin we have
demonstrated, together with its ‘adherens junction’ role in
cell culture models, we hypothesize that Jouberin defects
may compromise both epithelial integrity and cell–cell
signalling. Defective adherens junctions within the collecting
duct would reduce the osmotic gradient for effective
water reabsorption leading to polyuria. A more limited
expression of Jouberin along the nephron may account for
the milder cystic phenotype seen in NPHP kidneys, as
compared to autosomal-dominant polycystic kidney disease,
where cyst formation may occur at any segment, as
polycystin-1 and -2 proteins are expressed along the entire
length of the nephron.
In conclusion, we characterize the JBTS protein Jouberin
in terms of a novel protein–protein interaction with
OverlayAcetylated α-tubulinJouberin
Figure 6 | Jouberin colocalizes with acetylated a-tubulin in the primary cilia of renal epithelial cells. mIMCD3 cells were grown on
glass coverslips for 96 h past confluency before fixation in paraformaldehyde. Above cell surface epifluorescent images were captured
after staining with anti-Jouberin (left) and acetylated a-tubulin (middle) and demonstrates an association with ciliary structures
(right: Jouberin, green; acetylated a-tubulin, red). Bar¼ 5 mm.
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nephrocystin-1, subcellular localization in cultured renal
cells, and tissue distribution within the human kidney.
Models of AHI1 knockdown are now required to test
functional roles of Jouberin in these specific locations.
MATERIALS AND METHODS
Real-time-PCR of Jouberin from whole tissues and cell culture
lines
Total RNA was obtained from whole mouse kidney, whole mouse
brain, and cell lines HEK293, MDCK, and mIMCD3 cells using
TRIZOL (Sigma, Gillingham, Dorset, UK) extraction reagent.
Human kidney and brain total RNA was obtained from a
commercial library (Clontech, Saint-Germain-en-Laye, France).
RNA (2 mg) was reverse transcribed according to the protocol using
SuperScript III Reverse Transcriptase (Invitrogen, Paisley, UK).
Negative controls omitted reverse transcriptase.
PCR used HotStartTaq DNA polymerase (Qiagen, Crawley, West
Sussex, UK) with 2ml reverse-transcribed RNA in a 20ml reaction.
Oligonucleotide primer concentration was 0.5mM. PCR amplification
was over 30 cycles. Gene-specific oligonucleotide primers for human,
mouse, and Canis Jouberin were designed from available database
sequences (Ensembl). For human Jouberin primers were 5-TTGG
AACCCAGAAACAGGAG-3 and 5-ATCTCTTGAGCGGTCAGCAT-3,
predicted product size 474 bp. For mouse Jouberin primers were 5-AG
ATCGCACAGGAAATGGAG-3 and 5-AAGCACTTGGGATGAACTG
G-3, predicted product size 578 bp, for Canis Jouberin primers were
5-CCGCTCATCACATTCAACAC-3 and 5-CCGCTCATCACATTCAA
CAC-3, predicted product size 329 bp. PCR products were analyzed
using agarose gel electrophoresis.
Jouberin antibody generation
Rabbit anti-Jouberin polyclonal antibody (Ab737) was generated using
a synthetic peptide approach by CovalAb, Cambridge, UK. Purified
synthetic peptide spanning human Jouberin amino acids 1121–1135
(Figure 1) was used to raise the immune response in rabbits. A second
rabbit anti-Jouberin polyclonal antibody (Ab736) was prepared in a
similar manner, using and antigenic peptide spanning human Jouberin
amino acids 379–393 (Figure 1). Immunopurification of antipeptide
antibodies using a sepharose column was carried out.
Tagged protein generation
Human and murine Jouberin and human nephrocystin-1 sequence
was PCR amplified from IMAGE clones (IMAGE: 3908210, 6467369,
OverlayAQP2Jouberin-Ab737
Jouberin-Ab737
Jouberin-Ab737 Jouberin-Ab737 Pre-immune sera
OverlayAQP2
Figure 7 | Jouberin is expressed in human renal collecting duct cells. Human kidney sections were stained with anti-Jouberin (Ab737).
(a) Single antibody-stained sections demonstrate Jouberin expression in a subset of nephron segments. A negative control using
preimmune sera for Ab737 is shown. Bar¼ 20mm. (b, c) Double antibody-stained sections using anti-Jouberin and anti-aquaporin-2 (AQP).
Overlayed images show that Jouberin expression is limited to collecting duct segments, stained positively with AQP2. Bar¼ 20mm.
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and 4284129, respectively) then subcloned into pENTR/D-TOPO
(Invitrogen). Direct sequencing verified sequence fidelity and
reading frame. Clones were then switched to DEST 53 (N-terminal
GFP) and/or DEST (N-terminal V5) using the Gateway system
(Invitrogen). Full-length human nephrocystin and p130Cas both
tagged with 3XFLAG were purchased from GeneCopoeia, Berlin,
Germany, site-directed mutagenesis of Jouberin to create the
R830W missense mutation was carried out using mutagenic primers
50-AGAATTATGGATCTCtGGATATTAGTAGCAAG-30 and 50-CTTG
CTACTAATATCCaGAGATCCATAATTCT-30 and PCR protocols as
per QuikChange site-directed mutagenesis (Stratagene, La Jolla, CA,
USA). Direct sequencing of clones was performed to verify the
presence of the mutation.
Western analysis of endogenous and exogenous Jouberin
MDCK, mIMCD3, HEK293, adult mouse kidney, adult mouse
brain, and HEK293 transfected with human Jouberin DEST 53
(N-terminal GFP) were solubilized in protein extraction buffer
(4 M urea, 125 mM Tris pH6.8, 4% SDS, 10% glycerol, 5% b-mercap-
toethanol, and 0.02% bromophenol blue). Protein samples were
heated to 95 1C for 5 min and then run out on 6% SDS–polyacry-
lamide gel electrophoresis. Samples were then electrophoretically
transferred from the gel to Amersham, Buckinghamshire, UK
Hybond-C-extra nitrocellulose. Membranes were blocked in 5%
milk (Marvel, Premier Foods, St Albans, UK) in Tris-buffered saline
Tween-20 for 1 h at room temperature (RT). Endogenous and
exogenous Jouberin was detected by incubating with the rabbit anti-
Jouberin antibody (Ab737 or Ab736; 1:100) in blocking buffer for
1 h at RT. Three 15 min washes Tris-buffered saline Tween-20 were
carried out at RT. The secondary antibody was polyclonal swine
anti-rabbit conjugated to horseradish peroxidase (HRP; Dako, Ely,
Cambridgeshire, UK) diluted 1:2000 in blocking buffer. Exogenous
Jouberin was also detected with anti-GFP conjugated to HRP (Santa
Cruz, CA, USA) 1:5000. Membranes were developed using the super
signal west Dura extended duration substrate system (Pierce
Biotechnology, Rockford, IL, USA). For the blocking/competition
control Jouberin antibody was combined with a fivefold (by weight)
excess of blocking peptide and then incubated for 2 h at RT. Jouberin
antibody preimmune serum diluted in blocking buffer to the same
final concentration as AHI1 antibody was used as a further control.
Coimmunoprecipitation
HEK293s were transiently co-transfected with either human Jouberin-
V5 and human nephrocystin-1-3XFLAG or mouse Jouberin-V5 and
human nephrocystin-1-3XFLAG using Lipofectamine 2000. After 24 h
cells were washed in phosphate-buffered saline (PBS), pelleted, and
lysed in NP-40 buffer (150 mM sodium chloride, 0.5% NP-40, 50 mM
Tris pH 7.4, phenylmethanesulphonylfluoride, and protease inhibi-
tors). The lysate was centrifuged for 20 min at 10,000 g at 4 1C and the
supernatant was precleared with protein G sepharose beads (GE
Healthcare, Giles, Buckinghamshire, UK). After removal of protein G
the supernatant was then incubated overnight with protein G and 1mg
of either anti-V5 (Invitrogen), anti-Flag (Sigma), or mouse IgG
(Sigma) at 4 1C. The beads were washed extensively in lysis buffer and
bound proteins resolved by 6% SDS–polyacrylamide gel electrophor-
esis as described above. Flag-tagged proteins were detected as described
above using with anti-Flag-conjugated to HRP (Sigma) 1:10,000 and
V5-tagged proteins were detected with anti-V5 conjugated to HRP
(Invitrogen) 1:5000.
For endogenous coimmunoprecipitation studies, HEK293 cells
were lysed in NP-40 buffer. The lysate was centrifuged for 20 min at
10,000 g at 4 1C and the supernatant was precleared with protein A
(Pierce). After removal of protein A the supernatant was then
incubated overnight with protein A and 2 mg of either rabbit anti-
Jouberin, rabbit anti-nephrocystin-1 (Santa Cruz), or rabbit IgG at
4 1C. The beads were washed extensively in lysis buffer and bound
proteins resolved by 6% SDS–polyacrylamide gel electrophoresis as
described above. Nephrocystin-1 was detected using rabbit anti-
nephrocystin-1 (Santa Cruz) 1:500 and anti-rabbit HRP 1:2000
(Dako).
Yeast direct interaction studies
Clones of human Jouberin, human nephrocystin-1, and domain
subclones were used as bait/prey, fused to the GAL4 DNA-binding
domain in the pDEST32 vector as bait and/or fused to the Gal4
activation domain fusion vector (pDEST22; Invitrogen). Plasmids
were transformed into competent MaV203 yeast cells using the
lithium acetate method (as described in28). Interaction experiments
were performed using –His, –Leu, and –Trp-deficient medium
containing 25 mM 3-aminotriazole. Colony growth was compared to
two negative controls (respective plasmids without insert) and four
positive control yeast strains for different interaction strength
(as previously described28).
Exogenous expression and immunohistochemistry
MDCK cells were transfected with the human Jouberin–GFP
construct using a nucleofector (Amaxa Biosystems, Cologne,
Germany). A total of 1 106 cells were transfected with 5 mg of
cDNA construct. Cells were incubated at 37 1C for 48 h before fixing
in 4% paraformaldehyde. mIMCD3 cells were grown to confluence
for endogenous Jouberin expression and fixed in 100% methanol for
2 min at 20 1C or 4% paraformaldehyde in PBS for 1 h then
permeabilized using 1 PBS/0.5% Triton X-100 only for paraf-
ormaldehyde-fixed tissue. All cells were blocked for 1 h at RT in 10%
bovine serum albumin in PBS. Endogenous Jouberin was detected
with anti-Jouberin (Ab737; 1:100) overnight at 4 1C. Cells
transfected with Jouberin–GFP were double stained with either
mouse-acetylated a-tubulin (1:1000; Sigma) or mouse anti- g-
tubulin (1:100; Sigma) for 1 h at RT. Cells were washed three times
with PBS then incubated with the appropriate secondary antibody;
fluorescein-conjugated goat anti-rabbit (Stratech Scientific Ltd,
Suffolk, UK; 1:200) for 1 h at RT or Alexa Fluor 594 donkey anti-
mouse (1:200; Invitrogen) for 1 h at RT. Human kidney sections
(from the healthy pole of nephrectomy specimens following
informed consent and full ethical approval) were flash frozen in
liquid nitrogen and sectioned. Sections were fixed in methanol for
2 min at 20 1C before antibody staining. For single staining,
following blocking with 10% bovine serum albumin in PBS,
Jouberin was detected using (rabbit) anti-Jouberin (Ab737; 1:100)
overnight at 4 1C and fluorescein isothiocyanate goat anti-rabbit
secondary antibodies (1:200; Stratech). For double staining,
following blocking with 10% bovine serum albumin in PBS,
Jouberin was detected using (rabbit) anti-Jouberin (Ab737)
(1:100) overnight at 4 1C and secondary anti-rabbit Cy3 (Sigma),
raised in sheep (1:200) for 1 h at RT. Goat primary AQP2 antibodies
(Santa Cruz; 1:250; 1 h at RT) were used to detect collecting duct
cells, secondarily detected with donkey anti-goat FITC (Jackson
Immuno Research, Westgrove, PA, USA; 1:100) for 1 h at RT.
Control sections omitted Jouberin or AQP2 primary antibodies.
Additional controls for anti-Jouberin antibodies used rabbit
preimmune sera. Samples were analyzed using the Carl Zeiss LSM
510 confocal microscope.
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